SCHEMBL5472182

SCHEMBL5472182

Nc1ncnc2scc(C(=O)Nc3cccc(NC(=O)Nc4cccc(F)c4)c3)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK3 Q13188 11/20 0.73
MARK3 P27448 10/20 0.73
MAP4K4 O95819 10/20 0.73
AXL P30530 10/20 0.73
MAP4K2 Q12851 10/20 0.73
SLK Q9H2G2 10/20 0.73
MKNK2 Q9HBH9 9/20 0.73
MARK2 Q7KZI7 9/20 0.73
MINK1 Q8N4C8 8/20 0.73
PLK4 O00444 8/20 0.73
LIMK1 P53667 8/20 0.73
CLK4 Q9HAZ1 8/20 0.73
HIPK4 Q8NE63 8/20 0.73
ROCK1 Q13464 8/20 0.73
CDK1 P06493 7/20 0.73
CSNK1G2 P78368 7/20 0.73
CAMK2G Q13555 7/20 0.73
CAMK2D Q13557 7/20 0.73
BRSK1 Q8TDC3 6/20 0.73
NTRK2 Q16620 6/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721626 0.97 STK3 (0.78) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL4722113 0.93 MARK3 (0.78) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL4721372 0.90 PLK4 (0.89) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL5474509 0.89 AURKA (0.63) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL5474913 0.88 PLK4 (0.71) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL5472372 0.88 PLK4 (0.94) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL5464061 0.87 STK3 (0.64) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL4720555 0.87 PLK4 (0.89) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL4761640 0.86 PLK4 (0.81) STK3MARK3MAP4K4AXLMAP4K2
SCHEMBL4719895 0.85 PLK4 (0.67) STK3MARK3MAP4K4AXLMAP4K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135387-A1 Inhibitors of protein kinases ABBOTT LABORATORIES 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135387-A1 Inhibitors of protein kinases MAP3K20, PACSIN2, MAP4K2 STK3 237/4885MARK3 402/4885MAP4K4 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.